Form 4: Carrie Smith Cox Acquires Shares and Options in Cartesian Therapeutics

Director Carrie Smith Cox reports acquisition of common stock and stock options in Cartesian Therapeutics.

Summary

• On January 2, 2025, Carrie Smith Cox, a director of Cartesian Therapeutics, acquired 2,600 shares of common stock and 8,000 stock options.
• The common stock was acquired at a price of $0.
• Following the transaction, Cox directly owns 15,629 shares of common stock and 8,000 stock options with an exercise price of $16.93, expiring on January 1, 2035.
• Cox also owns 8,266 stock options with an exercise price of $19.656, expiring on January 1, 2034.
• The reported securities amounts have been adjusted to reflect a 1-for-30 reverse stock split that occurred on April 4, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director increasing their stake in the company is generally viewed favorably, but the filing itself is a routine regulatory disclosure.

Positives

• A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in the company's securities.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates